In order to deliver a personalised, responsive service and to improve the site, we remember and store information about how you use it. This is done using simple text files called cookies which sit on your computer. By continuing to use this site and access its features, you are consenting to our use of cookies. To find out more about the way drugeruptiondata.com uses cookies please read our 'Cookie Policy'.
- TRADE NAME: Viberzi (Forest)
- INDICATIONS: Irritable bowel syndrome with diarrhea
- CLASS: Opioid mu receptor agonist
- HALF-LIFE: 4–6 hours
- FDA APPROVAL DATE: 05/27/2015
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Alfentanil, Alosetron, Anticholinergics, Atazanavir, Bupropion, Ciprofloxacin, Clarithromycin, Cyclosporine, Dihydroergotamine, Eltrombopag, Ergotamine, Fentanyl, Fluconazole, Gemfibrozil, Lopinavir, Opioids, Paroxetine Hydrochloride, Paroxetine Mesylate, Pimozide, Quinidine, Rifampin, Ritonavir, Rosuvastatin, Saquinavir, Sirolimus, Tacrolimus, Tipranavir - PREGNANCY: Insufficient evidence to inform drug-associated risk
Contra-indicated in patients with known or suspected biliary duct obstruction, or sphincter of Oddi disease or dysfunction; alcoholism, alcohol abuse, alcohol addiction, or drink more than 3 alcoholic beverages/day; a history of pancreatitis; structural diseases of the pancreas, including known or suspected pancreatic duct obstruction; severe hepatic impairment (Child-Pugh Class C); severe constipation or sequelae from constipation, or known or suspected mechanical gastrointestinal obstruction.
Please login to view the rest of this drug profile.
Page last updated 07/31/2023
